The drostanolone propionate-treated animals show a marked weight increase caused by the anabolic effect of the compound. The difference growing in the course of the experiment between gross body weight and net body weight can be interpreted as the actual increase of weight of the tumors. The increase of gross body weight in the group treated with the combination corresponds to that of the group treated with drostanolone propionate alone.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||10 mM in DMSO|
Treatment of Advanced Breast Carcinoma with Drostanolone Propionate A Case Report
N. M. Heney, et al, Bristol Med Chir J. 1970 Jul;85(3): 75–76.
VH-298 is a potent VHL inhibitor that stabilizes HIF-α and elicits a hypoxic response via a different mechanism, with a Kd value of 80 to 90 nM.
6-Methylcoumarin belongs to the class of organic compounds known as coumarins and derivatives.
BTTAA is a Cu(I)-stabilizing ligand, whch performs potently with ubiquitin Glu18AzF.
Ezutromid (also known as BMN-195 and SMT C1100) is a first orally bioavailable utrophin's translation modulator with EC50 of 0.4 uM.
GNE-495 is a potent and selective MAP4K4 inhibitor with an IC50 of 3.7 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.